According to YH Research, the global market for PARG Inhibitor should grow from US$ 0.32 million in 2025 to US$ 1.60 million by 2032, with a CAGR of 19.7% for the period of 2026-2032.

A PARG inhibitor blocks poly(ADP-ribose) glycohydrolase, which removes poly(ADP-ribose) chains during cellular DNA-damage responses. Preventing this turnover can disrupt replication-fork recovery and increase replication stress in susceptible tumour cells. Unlike PARP inhibition, it acts on polymer degradation rather than synthesis. Development requires selective engagement, sufficient intracellular exposure, pharmacodynamic evidence and a therapeutic window between tumour and normal proliferating tissue. Clinical value depends on tolerable, durable activity in defined populations, not an assumption that all PARP-resistant cancers respond.

Key Findings
PARG inhibition targets polymer removal within DNA damage response pathways
Clinical development separates monotherapy testing from emerging combination strategies
Biomarker selection must be validated rather than borrowed from PARP
Market Trends
PARG development is moving from target rationale into human dose selection and combination testing. IDE161 is being evaluated with a TOP1-payload ADC, and ETX-19477 has a first-in-human programme. DAT-2645, SYN608 and QLS1403 provide distinct Chinese development routes. Exposure, pharmacodynamics and reproducible cohort activity increasingly determine progress, with different evidence levels requiring separate interpretation.

Market Dynamics
Drivers
Impaired fork protection or high replication stress creates a rationale for disrupting PARG-mediated turnover. Unmet needs after existing DNA-repair therapies support clinical investment. Current direct demand is for controlled evaluation and translational assays rather than routine hospital drug purchasing.

Restraints
PARG also participates in normal DNA responses, so an adequate therapeutic window is not guaranteed. Early cohorts provide incomplete information on durability and uncommon toxicity. Without an approved label and pricing evidence, revenue projections remain less grounded than development milestones.

Opportunities
TOP1-payload combinations can test whether impaired repair of payload-induced lesions adds antitumour activity. Overlapping toxicity requires an independently evaluated schedule. Molecularly selected ovarian and breast cancer studies offer another route, but PARP resistance alone is not a validated universal selection rule.

Challenges
Preclinical biomarker signals may not predict benefit across heterogeneous human tumours. Prospective sampling, consistent assays and follow-up are needed to separate activity from cohort-selection effects. Funding continuity and feasible comparative trials determine whether dose-escalation findings can reach registration.

Industry Chain Analysis
Enzyme assays, chemistry and replication-stress models initiate PARG programmes. Synthesis and formulation teams produce clinical material; sponsors, hospitals and laboratories coordinate escalation, exposure analysis and pharmacodynamic sampling. Value currently resides in intellectual property and human proof of concept. Licensing and research contracts are not finished-drug sales. A commercial chain additionally requires registration, reproducible GMP scale-up, distribution and a payable treatment pathway.

Segment Insights
IDE161 combines dose optimization with clinical combination work, making schedule and pharmacodynamic compatibility central. ETX-19477 has first-in-human development and company updates on initial patient data; these do not establish comparative superiority. DAT-2645 provides a Chinese clinical route. SYN608 has documented clinical authorization, but patient outcomes must not be inferred from permission to start a trial. QLS1403 has company-disclosed preclinical evidence and is classified at that verified level here. The residual molecule category accommodates later assets without turning undisclosed compounds or reagent catalogues into established therapeutic competitors.

Downstream Market Opportunities
Ovarian studies must record platinum resistance, molecular criteria and prior therapy. Breast cohorts need separate interpretation by hormone receptors, BRCA status and treatment history. Endometrial combinations must show PARG contribution beyond the partner. Small-cell lung cancer TOP1-payload combinations address a different context and cannot inherit ovarian response assumptions. Other tumour cohorts remain exploratory until activity and a registration strategy are established.

Regional Insights
The United States hosts important IDE161 and ETX-19477 programmes. China contributes original development through Danatlas, SynRx and Qilu, with Chinese trials and US authorization appearing in different projects. These describe research geography, not drug-sales shares. Tissue access, trial capacity and previous treatment affect cross-region data transferability. European and Japanese participation may develop later, but current evidence does not justify assigning commercial totals to those regions.

Competitive Landscape Analysis
Representative companies include IDEAYA Biosciences, 858 Therapeutics, Danatlas Pharmaceuticals, SynRx Therapeutics and Qilu Pharmaceutical. IDEAYA advances IDE161 combinations; 858 develops ETX-19477 in humans; Danatlas progresses DAT-2645 clinically; SynRx has disclosed SYN608 authorization; Qilu has presented QLS1403 preclinical work. Competition centres on validated selection, exposure and safety and a credible registration route. Different stages and cohorts cannot produce a direct efficacy ranking or an approved manufacturing position.

Report Scope
This report studies and analyses global PARG Inhibitor status and future trends, to help determine the PARG Inhibitor market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for PARG Inhibitor, and provides market size (US$ million) and Year-over-Year growth, considering 2025 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights
(1) Global PARG Inhibitor market size, history data 2021-2025, and forecast data 2026 -2032, (US$ million)
(2) Global PARG Inhibitor by company, revenue, market share and industry ranking 2021-2026, (US$ million)
(3) Japan PARG Inhibitor by company, revenue, market share and industry ranking 2021-2026, (US$ million)
(4) Global PARG Inhibitor key consuming regions, consumption value and demand structure
(5) PARG Inhibitor industry chains, upstream, midstream and downstream
Market Segmentation
Market segment by players, this report covers
    IDEAYA Biosciences
    858 Therapeutics
    Danatlas Pharmaceuticals
    SynRx Therapeutics
    Qilu Pharmaceutical

Market segment by Type, covers
    IDE161
    ETX-19477
    DAT-2645
    SYN608
    QLS1403
    Others

Market segment by Biomarker Strategy, covers
    BRCA1/2 Mutation-selected
    Others

Market segment by Application, can be divided into
    Ovarian Cancer
    Breast Cancer
    Endometrial Cancer
    Small-cell Lung Cancer
    Others

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Chapter Outline
Chapter 1: to describe PARG Inhibitor product scope, global consumption value, Japan consumption value, development opportunities, challenges, trends, and policies
Chapter 2: Global PARG Inhibitor market share and ranking of major manufacturers, revenue, 2021-2026
Chapter 3: Japan PARG Inhibitor market share and ranking of major manufacturers, revenue, 2021-2026
Chapter 4: PARG Inhibitor industry chain, upstream, medium-stream, and downstream
Chapter 5: Segment by Type, consumption value, percent & CAGR, 2021-2032
Chapter 6: Segment by Application, consumption value, percent & CAGR, 2021-2032
Chapter 7: Segment in regional level, consumption value, percent & CAGR, 2021-2032
Chapter 8: Segment in country level, consumption value, percent & CAGR, 2021-2032
Chapter 9: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, revenue, gross margin
Chapter 10: Conclusions